Plant Lectin, MoMo30, Pressures HIV-1 to Select for Variants with Deleted N-Linked Glycosylation Sites

Momordica balsamina, a plant traditionally used in African medicine, contains a 30 kDa protein, MoMo30, previously identified by our group as an anti-HIV agent that binds glycan residues on the gp120 envelope protein, thereby acting as an entry inhibitor. In this study, we investigated whether prolonged exposure to MoMo30 exerts selective pressure on HIV-1 and induces mutations in the viral envelope (<i>env</i>) gene. T-lymphocyte cells were infected with HIV-1<sub>NL4-3</sub> and continuously treated with MoMo30 over a 24-day period. Viral RNA was isolated at regular intervals, and <i>env</i> genes were sequenced using the Illumina platform. RNA sequence variant calling was performed using iVar, which uses a frequency-based binomial test with a default allele frequency threshold of 3% and a minimum base quality of 20 and applies Bonferroni correction for multiple testing. The infectivity of the MoMo30-exposed virus was assessed using MAGI-CXCR4 cells, visualized by β-galactosidase staining, and compared to untreated controls. Statistical significance was determined via two-way ANOVA. MoMo30-treated HIV-1 exhibited multiple detrimental mutations in gp120 and gp41, including missense, nonsense, and frameshift changes. Notably, 32% of N-linked glycosylation sites were deleted in the treated virus, while no such changes were observed in controls. Functionally, the MoMo30-treated virus demonstrated a sixfold reduction in infectivity compared to untreated HIV-1<sub>NL4-3</sub>. These findings suggest that MoMo30 imposes genetic pressure on HIV-1<sub>NL4-3</sub>, selecting for mutations that reduce viral fitness.

Authors

Institutions

Publication Details

Journal
Viruses
Published
2025-06-27
DOI
https://doi.org/10.3390/v17070910
Primary Topic
HIV Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Plant Lectin, MoMo30, Pressures HIV-1 to Select for Variants with Deleted N-Linked Glycosylation Sites

Erick Gbodossou, Michael D. Powell, Kofi Kondwani, Amad Diop et al.
Viruses
HIV Research and Treatment
article

Plant Lectin, MoMo30, Pressures HIV-1 to Select for Variants with Deleted N-Linked Glycosylation Sites

Erick Gbodossou, Michael D. Powell, Kofi Kondwani, Amad Diop, Mahfuz Khan, Kenya DeBarros, Virginia Floyd, Morgan I. Coleman, Vincent C. Bond, Valerie Montgomery Rice
article en

Abstract

Momordica balsamina, a plant traditionally used in African medicine, contains a 30 kDa protein, MoMo30, previously identified by our group as an anti-HIV agent that binds glycan residues on the gp120 envelope protein, thereby acting as an entry inhibitor. In this study, we investigated whether prolonged exposure to MoMo30 exerts selective pressure on HIV-1 and induces mutations in the viral envelope (<i>env</i>) gene. T-lymphocyte cells were infected with HIV-1<sub>NL4-3</sub> and continuously treated with MoMo30 over a 24-day period. Viral RNA was isolated at regular intervals, and <i>env</i> genes were sequenced using the Illumina platform. RNA sequence variant calling was performed using iVar, which uses a frequency-based binomial test with a default allele frequency threshold of 3% and a minimum base quality of 20 and applies Bonferroni correction for multiple testing. The infectivity of the MoMo30-exposed virus was assessed using MAGI-CXCR4 cells, visualized by β-galactosidase staining, and compared to untreated controls. Statistical significance was determined via two-way ANOVA. MoMo30-treated HIV-1 exhibited multiple detrimental mutations in gp120 and gp41, including missense, nonsense, and frameshift changes. Notably, 32% of N-linked glycosylation sites were deleted in the treated virus, while no such changes were observed in controls. Functionally, the MoMo30-treated virus demonstrated a sixfold reduction in infectivity compared to untreated HIV-1<sub>NL4-3</sub>. These findings suggest that MoMo30 imposes genetic pressure on HIV-1<sub>NL4-3</sub>, selecting for mutations that reduce viral fitness.

VirusesVol. 17(7)
PROMETRA International (SN), Morehouse School of Medicine (US)
Ford Foundation, National Institute on Minority Health and Health Disparities
Good health and well-being
Openalex Percentile: Top 83%
HIV Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.